These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 19211665)

  • 1. Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria.
    Yilmaz MI; Axelsson J; Sonmez A; Carrero JJ; Saglam M; Eyileten T; Caglar K; Kirkpantur A; Celik T; Oguz Y; Vural A; Yenicesu M; Lindholm B; Stenvinkel P
    Clin J Am Soc Nephrol; 2009 Mar; 4(3):535-41. PubMed ID: 19211665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.
    Yilmaz MI; Carrero JJ; Martín-Ventura JL; Sonmez A; Saglam M; Celik T; Yaman H; Yenicesu M; Eyileten T; Moreno JA; Egido J; Blanco-Colio LM
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1174-81. PubMed ID: 20430947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.
    Eyileten T; Sonmez A; Saglam M; Cakir E; Caglar K; Oguz Y; Vural A; Yenicesu M; Yilmaz MI
    Nephrology (Carlton); 2010 Mar; 15(2):225-9. PubMed ID: 20470283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway?
    Yilmaz MI; Sonmez A; Saglam M; Yaman H; Cayci T; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Yenicesu M; Axelsson J
    Nephrol Dial Transplant; 2010 Oct; 25(10):3250-6. PubMed ID: 20348148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy.
    Yilmaz MI; Sonmez A; Saglam M; Kurt YG; Unal HU; Karaman M; Gok M; Cetinkaya H; Eyileten T; Oguz Y; Vural A; Mallamaci F; Zoccali C
    Am J Nephrol; 2014; 40(3):208-14. PubMed ID: 25324042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Corrected Inflammation, Oxidative Stress and Endothelial Dysfunction on Fmd Levels in Patients with Selected Chronic Diseases: A Quasi-Experimental Study.
    Yilmaz MI; Romano M; Basarali MK; Elzagallaai A; Karaman M; Demir Z; Demir MF; Akcay F; Seyrek M; Haksever N; Piskin D; Cimaz R; Rieder MJ; Demirkaya E
    Sci Rep; 2020 Jun; 10(1):9018. PubMed ID: 32488098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma pentraxin 3 is a more potent predictor of endothelial dysfunction than high-sensitive C-reactive protein.
    Yasunaga T; Ikeda S; Koga S; Nakata T; Yoshida T; Masuda N; Kohno S; Maemura K
    Int Heart J; 2014; 55(2):160-4. PubMed ID: 24632958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.
    Yilmaz MI; Saglam M; Sonmez A; Caglar K; Cakir E; Kurt Y; Eyileten T; Tasar M; Acikel C; Oguz Y; Vural A; Yenicesu M
    Blood Purif; 2007; 25(4):327-35. PubMed ID: 17709915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease.
    Suliman ME; Yilmaz MI; Carrero JJ; Qureshi AR; Saglam M; Ipcioglu OM; Yenicesu M; Tong M; Heimbürger O; Barany P; Alvestrand A; Lindholm B; Stenvinkel P
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):976-85. PubMed ID: 18417746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
    Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.
    Ruggenenti P; Perna A; Gherardi G; Benini R; Remuzzi G
    Am J Kidney Dis; 2000 Jun; 35(6):1155-65. PubMed ID: 10845831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pentraxin-3 and adropin as inflammatory markers of early renal damage in type 2 diabetes patients.
    Li B; Tian X; Guo S; Zhang M; Li J; Zhai N; Wang H; Zhang Y
    Int Urol Nephrol; 2020 Nov; 52(11):2145-2152. PubMed ID: 32661627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of serum pentraxin 3 concentrations with diabetic nephropathy.
    Wang R; Zhang J; Hu W
    J Investig Med; 2016 Aug; 64(6):1124-7. PubMed ID: 27233528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.
    Fernández-Juárez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Lahera V; Casas L; Oliva J;
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1870-6. PubMed ID: 24135218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes.
    Yilmaz MI; Sonmez A; Ortiz A; Saglam M; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Çakar M; Egido J; Altun B; Yenicesu M; Blanco-Colio LM; Carrero JJ
    Clin J Am Soc Nephrol; 2011 Apr; 6(4):785-92. PubMed ID: 21330486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophil-dependent pentraxin-3 and reactive oxygen species production modulate endothelial dysfunction in haemodialysis patients.
    dell'Oglio MP; Simone S; Ciccone M; Corciulo R; Gesualdo M; Zito A; Cortese F; Castellano G; Gigante M; Gesualdo L; Grandaliano G; Pertosa GB
    Nephrol Dial Transplant; 2017 Sep; 32(9):1540-1549. PubMed ID: 27915246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy.
    Fernández-Juárez G; Villacorta Perez J; Luño Fernández JL; Martinez-Martinez E; Cachofeiro V; Barrio Lucia V; Tato Ribera AM; Mendez Abreu A; Cordon A; Oliva Dominguez JA; Praga Terente M
    Nephrology (Carlton); 2017 May; 22(5):354-360. PubMed ID: 27003829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
    Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.